Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.39 |
| ▸ | BCHE | P06276 | 4/20 | 0.39 |
| ▸ | ACHE | P22303 | 4/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10243821 | 0.86 | OPRK1 (0.46) | MTNR1AMTNR1BBCHEACHEFAAH | |
| SCHEMBL10244077 | 0.86 | CYP2C19 (0.42) | BCHEACHEFAAHCYP3A4CYP2D6 | |
| SCHEMBL10243624 | 0.85 | ACHE (0.37) | MTNR1AMTNR1BBCHEACHEFAAH | |
| SCHEMBL10243833 | 0.85 | CYP2C19 (0.43) | BCHEACHEFAAHCYP2D6 | |
| SCHEMBL10244397 | 0.85 | MTNR1A (0.47) | MTNR1AMTNR1BBCHEACHEFAAH | |
| SCHEMBL10243444 | 0.85 | RAB9A (0.45) | — | |
| SCHEMBL10243851 | 0.85 | MTNR1A (0.47) | MTNR1AMTNR1BBCHEACHEFAAH | |
| SCHEMBL10243429 | 0.85 | MTNR1A (0.47) | MTNR1AMTNR1BBCHEACHEFAAH | |
| SCHEMBL10243869 | 0.85 | BCHE (0.37) | BCHEACHEFAAHCYP3A4CYP2D6 | |
| SCHEMBL10243497 | 0.84 | SLC22A1 (0.43) | MTNR1AMTNR1BCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | MTNR1A 2892/4885MTNR1B 2314/4885BCHE 1393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.